Reviva Announces Prel. Topline OLE Data Of Phase 3 RECOVER Study Of Brilaroxazine In Schizophrenia

(RTTNews) - Reviva Pharmaceuticals Holdings, Inc. (RVPH), Monday announced preliminary topline data for the open-label extension portion of the company's ongoing Phase 3 RECOVER study evaluating the long-term safety and tolerability of brilaroxazine in patients with schizophrenia.

For the trial, 435 patients were enrolled in the OLE across three dose groups, receiving brilaroxazine in 15 mg, 30mg and 50mg doses.

The biopharmaceutical company found that once daily brilaroxazine demonstrated favorable long-term safety and robust broad-spectrum efficacy sustained over 1-year.

Also, all three doses of brilaroxazine tested were efficacious and generally well-tolerated. It was well-tolerated with low rates of adverse events and discontinuation.

Laxminarayan Bhat, President, and CEO of Reviva, said, "We look forward to reporting the full data set from the OLE portion of the RECOVER study, which will include long-term safety, tolerability and efficacy data, as well as vocal and blood biomarker data as additional independent measures of efficacy, expected in the first quarter of 2025."

Currently, Reviva's stock is trading at $2.57, down 1.52 percent on the Nasdaq.